Is the GAIN Act a turning point in new antibiotic discovery?1

Brown, Eric D.
March 2013
Canadian Journal of Microbiology;Mar2013, Vol. 59 Issue 3, p153
Academic Journal
The United States GAIN (Generating Antibiotic Incentives Now) Act is a call to action for new antibiotic discovery and development that arises from a ground swell of concern over declining activity in this therapeutic area in the pharmaceutical sector. The GAIN Act aims to provide economic incentives for antibiotic drug discovery in the form of market exclusivity and accelerated drug approval processes. The legislation comes on the heels of nearly two decades of failure using the tools of modern drug discovery to find new antibiotic drugs. The lessons of failure are examined herein as are the prospects for a renewed effort in antibiotic drug discovery and development stimulated by new investments in both the public and private sector.


Related Articles

  • New antimicrobials on the horizon. Nnedu, Obi; Pankey, George // Infectious Disease News;Dec2013, Vol. 26 Issue 12, p8 

    The article presents several antibiotics that are being developed by pharmaceuticals companies as of December 2013 including beta-lactams and beta-lactamase inhibitors, the Tebipenem oral carbapanem in Japan and the Avibactam beta-lactamase from drug company AstraZeneca.

  • 12 Key Steps to Address USP Changes.  // Pharmaceutical Processing;Aug2009, Vol. 24 Issue 8, p22 

    The article discusses key procedures which the pharmaceutical industry should consider for them to be prepared in addressing the changes in the United States Pharmacopoeia (USP) General Microbiology. These suggestions from life science products provider Celsis International PLC include...

  • The Pharmaceutical Industry – Prices and Progress. Scherer, F.M. // New England Journal of Medicine;8/26/2004, Vol. 351 Issue 9, p927 

    The article looks at the economics of the pharmaceutical industry. Prescription drug sales in the U.S. for 2002 are reported. The pharmaceutical industry devotes a large portion of its profits to research and development. This has led to new therapeutic products. Drug patents leading to monopoly...

  • Documenting Pharmaceutical Development of Biotechnology-Derived Medicinal Products. Holloway, Chris; Cronin, Paul // BioPharm International;Aug2004 Supplement, Vol. 17, p36 

    Provides additional information to the section on pharmaceutical development of biotechnology-derived medicinal products contained in the Common Technical Document created by the International Conference on Harmonisation. Validity of the regulatory basis for pharmaceutical development in Europe;...

  • Defining The Borders.  // Pharmaceutical Technology Europe;Apr2005, Vol. 17 Issue 4, p17 

    The article focuses on pharmaceutical legislation and product development. One of the problems that has bedeviled pharmaceutical product development for many years is the uncertainty over what is a pharmaceutical and what is not. Some industry representatives argued that the current European...

  • CAN THIS PLANT TRANSFORM INDIAN PHARMA? Duncan, David Ewing // Fortune International (Europe);10/31/2005, Vol. 152 Issue 8, p76 

    This article discusses the malaria cure discovered by Ranbaxy Laboratories in India. Ranbaxy's synthetic cousin of the Chinese fever remedy artemisinin, which is more potent and less expensive to produce than the natural compound, offers hope to malaria patients, some one million of whom die...

  • Coaxing Pharma Out of the Gate. Agres, Ted // Drug Discovery & Development;Jun2005, Vol. 8 Issue 6, p14 

    The article discusses the impact of a proposed legislation related to the Project Bioshield that is likely to come up for discussion in the U.S. Congress in the year 2005. It is informed that the proposed new legislation would grant a raft of new incentives, such as patent extensions, liability...

  • Potential Interactions of the Orphan Drug Act and Pharmacogenomics: A Flood of Orphan Drugs and Abuses? Loughnot, David // American Journal of Law & Medicine;2005, Vol. 31 Issue 2/3, p365 

    Examines the potential interactions of the Organ Drug Act and pharmacogenomics in the U.S. Success of the law in encouraging development of previously unprofitable drugs; Utilization of pharmacogenomic technology by biotechnology and pharmaceutical companies to subdivide patients with the same...

  • One Step Forward for Small European Firms In Biotech. O'Donnell, Peter // BioWorld International;12/19/2007, Vol. 12 Issue 51, p4 

    The article reports on the decision of the European Parliament in 2007 to endorse the European Union's plan for research support for the pharmaceutical industry. The parliament voted through the proposed Innovative Medicines Initiative, adding special provisions to increase aid to small firms....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics